Tomaš MI - Search Results

1

Segregation of open Major Histocompatibility Class I conformers at the plasma membrane and during endosomal trafficking reveals conformation-based sorting in the endosomal system.

Mahmutefendić H, Blagojević G, Tomaš MI, Kučić N, Lučin P. Mahmutefendić H, et al. Among authors: tomas mi. Int J Biochem Cell Biol. 2011 Apr;43(4):504-15. doi: 10.1016/j.biocel.2010.12.002. Epub 2010 Dec 21. Int J Biochem Cell Biol. 2011. PMID: 21176792

2

Murine cytomegalovirus perturbs endosomal trafficking of major histocompatibility complex class I molecules in the early phase of infection.

Tomas MI, Kucić N, Mahmutefendić H, Blagojević G, Lucin P. Tomas MI, et al. J Virol. 2010 Nov;84(21):11101-12. doi: 10.1128/JVI.00988-10. Epub 2010 Aug 18. J Virol. 2010. PMID: 20719942 Free PMC article.

3

Early endosomal rerouting of major histocompatibility class I conformers.

Zagorac GB, Mahmutefendić H, Tomaš MI, Kučić N, Le Bouteiller P, Lučin P. Zagorac GB, et al. Among authors: tomas mi. J Cell Physiol. 2012 Jul;227(7):2953-64. doi: 10.1002/jcp.23042. J Cell Physiol. 2012. PMID: 21959869

4

Endosomal trafficking of open Major Histocompatibility Class I conformers--implications for presentation of endocytosed antigens.

Mahmutefendić H, Zagorac GB, Tomaš MI, Groettrup M, Momburg F, Lučin P. Mahmutefendić H, et al. Among authors: tomas mi. Mol Immunol. 2013 Sep;55(2):149-52. doi: 10.1016/j.molimm.2012.10.008. Epub 2012 Nov 27. Mol Immunol. 2013. PMID: 23200229 Review.

5

Landmarks of endosomal remodeling in the early phase of cytomegalovirus infection.

Karleuša L, Mahmutefendić H, Tomaš MI, Zagorac GB, Lučin P. Karleuša L, et al. Among authors: tomas mi. Virology. 2018 Feb;515:108-122. doi: 10.1016/j.virol.2017.12.001. Epub 2017 Dec 22. Virology. 2018. PMID: 29277005 Free article.

6

Different perforin expression in peripheral blood and prostate tissue in patients with benign prostatic hyperplasia and prostate cancer.

Tokmadžić VS, Tomaš MI, Sotošek S, Laškarin G, Dominović M, Tulić V, Dorđević G, Sustić A, Mrakovčić-Šutić I. Tokmadžić VS, et al. Among authors: tomas mi. Scand J Immunol. 2011 Oct;74(4):368-76. doi: 10.1111/j.1365-3083.2011.02569.x. Scand J Immunol. 2011. PMID: 21535078 Free article.

7

How activity of inflammatory bowel disease influences bone loss.

Orlic ZC, Turk T, Sincic BM, Stimac D, Cvijanovic O, Maric I, Tomas MI, Jurisic-Erzen D, Licul V, Bobinac D. Orlic ZC, et al. Among authors: tomas mi. J Clin Densitom. 2010 Jan-Mar;13(1):36-42. doi: 10.1016/j.jocd.2009.12.002. J Clin Densitom. 2010. PMID: 20171567

8

Comparative study of frequency of different lymphocytes subpopulation in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.

Sotosek S, Sotosek Tokmadzic V, Mrakovcic-Sutic I, Tomas MI, Dominovic M, Tulic V, Sutic I, Maricic A, Sokolic J, Sustic A. Sotosek S, et al. Among authors: tomas mi. Wien Klin Wochenschr. 2011 Dec;123(23-24):718-25. doi: 10.1007/s00508-011-0096-7. Epub 2011 Nov 23. Wien Klin Wochenschr. 2011. PMID: 22105113

9

The significance of serum thyroglobulin measurement before and after the treatment of toxic nodular goiter with 131I.

Bonefačić B, Crnčić TB, Tomaš MI, Girotto N, Ivanković SG. Bonefačić B, et al. Among authors: tomas mi. Nucl Med Commun. 2020 Apr;41(4):344-349. doi: 10.1097/MNM.0000000000001153. Nucl Med Commun. 2020. PMID: 31977753

10

Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.

Schulman CC, De Sy W, Vandendris M, Tomas M, Santoni JP. Schulman CC, et al. Acta Urol Belg. 1994 Dec;62(4):15-21. Acta Urol Belg. 1994. PMID: 7540794 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page